Monitoring and optimising cognitive function in cancer patients: Present knowledge and future directions
Standard
Monitoring and optimising cognitive function in cancer patients: Present knowledge and future directions. / Schagen, S.B.; Klein, M.; Reijneveld, J.C.; Brain, E.; Deprez, S.; Joly, F.; Scherwath, A.; Schrauwen, W.; Wefel, J.S.
in: EJC Suppl, Jahrgang 12, Nr. 1, 06.2014, S. 29-40.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Monitoring and optimising cognitive function in cancer patients: Present knowledge and future directions
AU - Schagen, S.B.
AU - Klein, M.
AU - Reijneveld, J.C.
AU - Brain, E.
AU - Deprez, S.
AU - Joly, F.
AU - Scherwath, A.
AU - Schrauwen, W.
AU - Wefel, J.S.
PY - 2014/6
Y1 - 2014/6
N2 - Abstract The potentially detrimental effects of cancer and related treatments on cognitive functioning are emerging as a key focus of cancer survivorship research. Many patients with central nervous system (CNS) or non-CNS tumours develop cognitive problems during the course of their disease that can result in diminished functional independence. We review the state of knowledge on the cognitive functioning of patients with primary and secondary brain tumours at diagnosis, during and after therapy, and discuss current initiatives to diminish cognitive decline in these patients. Similarly, attention is paid to the cognitive sequelae of cancer and cancer therapies in patients without CNS disease. Disease and treatment effects on cognition are discussed, as well as current insights into the neural substrates and the mechanisms underlying cognitive dysfunction in these patients. In addition, rehabilitation strategies for patients with non-CNS disease confronted with cognitive dysfunction are described. Special attention is given to knowledge gaps in the area of cancer and cognition, in CNS and non-CNS diseases. Finally, we point to the important role for cooperative groups to include cognitive endpoints in clinical trials in order to accelerate our understanding and treatment of cognitive dysfunction related to cancer and cancer therapies.
AB - Abstract The potentially detrimental effects of cancer and related treatments on cognitive functioning are emerging as a key focus of cancer survivorship research. Many patients with central nervous system (CNS) or non-CNS tumours develop cognitive problems during the course of their disease that can result in diminished functional independence. We review the state of knowledge on the cognitive functioning of patients with primary and secondary brain tumours at diagnosis, during and after therapy, and discuss current initiatives to diminish cognitive decline in these patients. Similarly, attention is paid to the cognitive sequelae of cancer and cancer therapies in patients without CNS disease. Disease and treatment effects on cognition are discussed, as well as current insights into the neural substrates and the mechanisms underlying cognitive dysfunction in these patients. In addition, rehabilitation strategies for patients with non-CNS disease confronted with cognitive dysfunction are described. Special attention is given to knowledge gaps in the area of cancer and cognition, in CNS and non-CNS diseases. Finally, we point to the important role for cooperative groups to include cognitive endpoints in clinical trials in order to accelerate our understanding and treatment of cognitive dysfunction related to cancer and cancer therapies.
KW - Cognitive function
KW - Cancer
U2 - http://dx.doi.org/10.1016/j.ejcsup.2014.03.003
DO - http://dx.doi.org/10.1016/j.ejcsup.2014.03.003
M3 - SCORING: Journal article
VL - 12
SP - 29
EP - 40
JO - EJC Suppl
JF - EJC Suppl
SN - 1359-6349
IS - 1
ER -